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Abstract
Background: Neurofibrillary tangles (NFTs) are intraneuronal aggregates associated with several
neurodegenerative diseases including Alzheimer's disease. These abnormal accumulations are
primarily comprised of fibrils of the microtubule-associated protein tau. During the progression of
NFT formation, disperse and non-interacting tau fibrils become stable aggregates of tightly packed
and intertwined filaments. Although the molecular mechanisms responsible for the conversion of
disperse tau filaments into tangles of filaments are not known, it is believed that some of the
associated changes in tau observed in Alzheimer's disease, such as phosphorylation, truncation,
ubiquitination, glycosylation or nitration, may play a role.
Results: We have investigated the effects of tau phosphorylation by glycogen synthase kinase-3β
(GSK-3β) on tau filaments in an in vitro model system. We have found that phosphorylation by
GSK-3β is sufficient to cause tau filaments to coalesce into tangle-like aggregates similar to those
isolated from Alzheimer's disease brain.
Conclusion: These results suggest that phosphorylation of tau by GSK-3β promotes formation of
tangle-like filament morphology. The in vitro cell-free experiments described here provide a new
model system to study mechanisms of NFT development. Although the severity of dementia has
been found to correlate with the presence of NFTs, there is some question as to the identity of
the neurotoxic agents involved. This model system will be beneficial in identifying intermediates or
side reaction products that might be neurotoxic.
Background
Tau is a remarkably soluble neuronal microtubule-associ-
ated protein that normally functions to promote the
assembly and stabilization of the microtubule cytoskele-
ton. In Alzheimer's disease (AD) and other related neuro-
degenerative disorders, tau aggregates into straight and
paired helical filaments [1]. As these diseases progress, the
tau fibrils associate with one another to form large densely
packed networks of interwined filaments termed neurofi-
brillary tangles (NFTs). Although the level of NFT forma-
tion has been shown to correlate with the severity of
dementia [2,3], it is unclear whether NFT formation is
neurotoxic. There are examples of NFT formation that cor-
relate with neurodegeneration [4-6] and also examples of
neurodegeneration in the absence of NFT formation [7-9].
It has even been suggested that NFT formation is protec-
tive for neurons [8]. However, NFTs are not inert patho-
logical lesions, but rather follow a definite developmental
progression (reviewed in [10]). It is possible that the neu-
rotoxic agents in AD may be intermediates in the develop-
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Therefore, detailed studies of NFT formation would be
beneficial to our understanding of toxic elements in AD.
Although polymerized tau is a major component of NFTs,
numerous other molecules have also been found associ-
ated with NFTs. Some of these include ubiquitin [11,12],
RNA [13], α-synuclein [14], GSK-3β [15], microtubule
affinity regulating kinase [16], and apolipoprotein E [17].
One of these nonfibrillar components, GSK-3β, appears
to have an active role in the pathological progression of
neurodegeneration. A drosophila model expressing both
human tau and the kinase GSK-3β exhibited enhanced
neurodegeneration and neurofibrillary pathology [4]
compared to expression of tau alone [9]. A similar result
was seen in a transgenic mouse model expressing a
mutated tau and the GSK-3β kinase [18]. To emphasize
the role of phosphorylation, treatment with the GSK-3β
inhibitor, lithium chloride, showed a reduction in neuro-
degeneration, tau phosphorylation, and tau pathology
when administered at early stages of neuropathology
[19,20]. Further evidence that phosphorylation may play
a role in NFT development was the discovery of highly
phosphorylated paired helical filaments, the form of fila-
mentous tau most prevalent in AD (reviewed in
[1,21,22]). Since GSK-3β appears to phosphorylate tau in
many of the same phosphorylation sites identified in
paired helical filaments of AD [23-25], it would appear
that phosphorylation by GSK-3β may play a role in forma-
tion of fibrils or NFTs.
We have tested the hypothesis that GSK-3β is involved in
some aspect of NFT formation by using an in vitro cell-
free model, where reagents can be clearly defined and con-
trolled. Cell-free polymerization models of tau have been
well established, generally using either arachidonic acid
(ARA) or heparin to initiate polymerization (reviewed in
[26]). However, use of these models to study effects of tau
phosphorylation on levels of tau polymer have been
inconclusive [27-32]. We have found that phosphoryla-
tion of tau by GSK-3β had little effect on polymerization
levels, although it had a significant role in the formation
of large localized accumulations of intertwined filaments.
These aggregates of tau fibrils were stable through sucrose
gradient centrifugation and migrated to the same region
as NFT-like structures isolated from AD brain [33,34]. Fur-
ther investigation of the reaction conditions producing
these NFT-like structures showed that the concentration
and nature of inducer(s) were important factors in defin-
ing aggregation characteristics of size and density. This
cell-free model of the formation of NFT-like accumula-
tions provides a useful tool for future studies to under-
stand how aggregation of tau polymer into NFT-like
structures might occur and which steps in the process
might potentially produce neurotoxic products.
Results
Phosphorylation of monomeric tau by GSK-3β
The in vitro phosphorylation of monomeric tau by GSK-
3β was dependent on both enzyme concentration and
incubation time (Figure 1A). Phosphorylation of tau was
detected by an upward shift in mobility upon SDS-PAGE
analysis reminiscent of hyper-phosphorylated tau in AD
[22]. The band shift represents an SDS-resistant confor-
mational change brought about by phosphorylation
rather than a molecular weight increase due to added
phosphates [35,36]. The in vitro phosphorylation, seen as
an upward band shift, was mostly complete after 20 h
incubation (Figure 1A, lanes 13, 14, and 15). With no
GSK-3β present (lane 13) the tau monomer migrates
approximately as a 74 kDa protein. With a kinase concen-
tration of 0.006 U/pmol tau (lane 14), the presence of
multiple bands suggest that tau is not fully phosphor-
ylated. At a kinase concentration of 0.018 U/pmol tau
(lanes 3, 6, 9, 12, and 15), band density measurements
showed that 8% shifted after 15 minutes, 16% by 30 min,
29% by one hour, 39% by 2 hours and 73% after 20
hours.
The number of phosphates incorporated per mole of tau
was quantified by utilizing [γ-32P] ATP as a substrate (Fig-
ure 1B). In comparing gel shift and radioactive phosphate
incorporation data (Figure 1B) a similar increase in phos-
phorylation over time was observed. At 20 h incubation
and a GSK-3β concentration of 0.018 U/pmol tau,
approximately 3 moles of phosphate were incorporated
per mole of tau, which is similar to the 2–4 mols phos-
phate incorporated/mol of tau in previously published
reports of in vitro GSK-3β phosphorylation of tau [37].
Sites phosphorylated by GSK-3β in tau monomer
We determined which tau sites were phosphorylated by
utilizing a panel of phosphorylation specific antibodies.
Thirteen dot blots containing concentrations of phospho-
rylated tau ranging from 1.56 to 800 ng per dot were
probed with these antibodies. Representative dot blots are
shown in Figure 2. Non-specific background binding to
non-phosphorylated tau was subtracted and titration
curves were plotted and analyzed (see Materials and
Methods). The blot probed with anti-S199 showed very
little non-specific antibody binding to non-phosphor-
ylated tau (Figure 2A); anti-T217 showed slightly more
non-specific binding (Figure 2B); and anti-S422 was the
least specific antibody under these conditions (Figure
2C). The titration curves of most of the antibodies resem-
bled that of anti-S199 (Figure 2D). These included anti-
T205, -S214, -T231, -S262, -S356, -S400, -S404, and -
S409. Anti-T212 and -S396 titration curves more closely
resembled that of anti-T217 (Figure 2E). Only anti-tau
S422 did not recognize a specific phosphorylation site
(Figure 2C, F) and therefore, served as a negative control.Page 2 of 14
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ng; only T212 differed, with a 1/2 max of roughly 12 ng.
Our phosphorylation specific antibody data was in agree-
ment with those sites recognized by the mass spectrome-
try data of Reynolds, et al. [37] and the combination of
two dimensional phosphopeptide mapping and mass
spectrometry used by Connell, et al. [38], except that we
identified additional sites, T205, S214, S262, S356, and
S409 that were not identified by mass spectrometry (Table
1). We did not have an antibody to the S235 site which
was identified in both the Connell, et al. and Reynolds, et
al. studies [37,38].
Kinetic analysis comparing polymerization of GSK-3β 
phosphorylated tau with polymerization of non-
phosphorylated tau
Thioflavine S (ThS) fluorescence intensity, a method tra-
ditionally used to obtain kinetic information regarding
tau filament formation in vitro [39] was used to compare
polymerization kinetics (Figure 3). Tau polymerization
Tau phosphorylation by GSK-3BFigure 1
Tau phosphorylation by GSK-3B. A) SDS-PAGE analysis of tau protein incubated for 20 h in the absence (lanes 1, 4, 7, 10, 
and 13) or the presence of 0.006 U GSK-3β per pmol tau (lanes 2, 5, 8, 11, 14) or 0.018 U GSK-3β per pmol tau (lanes 3, 6, 9, 
12, and 15). A definite band shift in the migration of phosphorylated tau can be detected with increasing time and kinase con-
centration. B) The amount of γ-32P incorporation over time using 0.018 U GSK-3β per pmol tau (open circles, right y-axis) is 
compared to the SDS-PAGE analysis in Panel A (open squares, left y-axis). Lines are drawn through the points to ease compar-
ison. Data represents a single trial.Page 3 of 14
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Tau sites phosphorylated by GSK-3β in an in vitro reactionFigure 2
Tau sites phosphorylated by GSK-3β in an in vitro reaction. Thirteen phosphorylation-site-specific antibodies were 
used to probe dot blots of GSK-3β phosphorylated tau. Panel A and B show two representative blots. Three repetitions of 
each phosphorylated tau concentration, ranging from 800 to 1.56 ng, were spotted on a blot, then probed with an anti-phos-
phorylation specific antibody (See Materials and Methods for details). To estimate non-specific background levels, each blot 
also included one spot of non-phosphorylated tau at each concentration. Following density analysis, the antibody titrations 
were plotted (Panels D and E) and 1/2 max concentrations were estimated. Anti-S422 antibody shown in Panel C, and its titra-
tion plot in Panel F, did not recognize phosphorylation and served as a negative control.
Molecular Neurodegeneration 2007, 2:12 http://www.molecularneurodegeneration.com/content/2/1/12reactions are described in detail in Materials and Methods.
The polymerization reactions were performed with opti-
mal or suboptimal ratios of ARA inducer to tau protein
concentrations. For polymerization purposes, an optimal
ratio of ARA inducer to tau is 75 μM ARA:2 μM tau; a sub-
optimal ratio is 25 μM ARA:2 μM tau [40]. The reaction
kinetics represented by an increase in ThS fluorescence
intensity were monitored for 20 h. At the optimal ratio of
ARA inducer to tau protein (labeled 75 μM), the slight
increase in polymerization of GSK-3β phosphorylated tau
observed at the end of the reaction was not significant
(Figure 3A) (P = 0.1788). However, at a suboptimal ratio
(labeled 25 μM) phosphorylated tau had a significant
increase in polymerization over non-phosphorylated con-
trol (Figure 3A) (P = 0.0142).
Assaying by ThS intensity allows for observation of
changes very early in the reaction and upon the addition
of ARA inducer there was a rapid and dramatic increase in
ThS fluorescence (Figure 3B), as has been previously
described [41]. This rapid early increase in ThS intensity
apparently registers a change in molecular structure but
does not measure filament formation per se [41]. At both
suboptimal and optimal inducer:protein ratios, the phos-
phorylated protein seemed to have a greater initial veloc-
ity of polymerization compared to non-phosphorylated
tau (Figure 3B), suggesting that phosphorylated protein is
either in an altered conformation or more rapidly adopts
a ThS positive conformation in the presence of ARA.
TEM analysis of filaments from GSK-3β phosphorylated 
tau
Polymerization samples of phosphorylated tau (induced
with 25 μM ARA) were taken from the 20 h time point in
the kinetic analysis described above and prepared for
TEM. The filaments produced in the GSK-3β phosphor-
ylated tau reactions were not distributed uniformly on the
Kinetic analysis of polymerization using GSK-3β phosphor-ylat d t uF gure 3
Kinetic analysis of polymerization using GSK-3β 
phosphorylated tau. A comparison between control (non-
phosphorylated, open symbols) and phosphorylated tau 
(filled symbols) showed that phosphorylation altered polym-
erization kinetics, particularly in the first 30 minutes of the 
reaction. Panel A shows kinetics over the entire 20-h reac-
tion time. Panel B shows only the first 30 minutes (the sec-
tion boxed by a dotted line in panel A). Two ratios of ARA 
inducer:tau protein were compared: a suboptimal ratio 
(labeled 25 μM, representing the concentration of ARA, dia-
monds) and an optimal ratio (labeled 75 μM, circles). The tau 
protein concentration was 2 μM for all kinetic reactions. 
Changes in ThS fluorescence intensity (y axis) was used to 
indicate the extent of polymerization and measurements 
were in arbitrary units (a.u.). Error bars are +/- SEM. Every 
40th data point was plotted for ease in interpretation.
Table 1: Tau sites phosphorylated by GSK-3β.
sites Reynoldsa Connellb Rankinc
T175 + *
T181 + *
S199 + + +
T205 +
T212 + + +
S214 +
T217 + + +
T231 + + +
S235 + + *
S262 +
S356 +
S396 + + +
S400 + + +
S404 + + +
S409 +
S422
Identification of in vitro phosphorylated sites by mass spectrometry
a Reynolds, et al. study [37]
b Connell, et al. study [38]
c Identification of in vitro phosphorylated sites by phosphorylation 
site-specific antibodies. Antibodies were unavailable for those sites 
marked with an asterisk. S422, not identified by either mass 
spectrometry or antibody analysis, was a negative control.Page 5 of 14
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(Figure 4A, C, and 4E). At higher magnifications (Figure
4B, D, and 4F), some filaments, although appearing to be
a part of the aggregate, were not touching (Figure 4, white
arrowheads); others seemed to be intertwined. Additional
configurations appeared to represent branching filaments
(Figure 4, white asterisk) as well as tendril-like fibers
bridging the lateral gap between larger adjacent filaments
(Figure 4, black arrowheads). The filaments within the
aggregates had an average width of 16 ± 4 nm, similar to
non-aggregated filaments seen in Figure 4, and to fila-
ments formed from non-phosphorylated tau (Figure 5A
and 5B).
The major advantage of an in vitro cell-free system as a
research tool is the ease with which various reagents (by
their addition/omission) can be examined for their effect
on a specific result, in this case the clustering or aggrega-
tion of filaments. Conventional, control reactions with
non-phosphorylated tau, performed under standard
polymerization conditions with either the suboptimal or
optimal ratios of ARA:tau protein (75 or 25 μM ARA,
respectively:2 μM tau protein) did not show filament clus-
tering (Figure 5A and 5B). Polymerization reaction condi-
tions are detailed in Materials and Methods. Since the 75
μM ARA TEM sample was diluted by a factor of ten
whereas the 25 μM ARA sample was diluted by a factor of
five, the TEM analysis appeared similar to the kinetic
study observations (Figure 3) in regard to filament mass.
TEM analysis of mock phosphorylation reactionsFigure 5
TEM analysis of mock phosphorylation reactions. 
Standard polymerization reactions containing 2 μM tau were 
induced with either a low (25 μM), or optimal (75 μM) con-
centration of ARA (Panels A and B, respectively). Panels C-F 
show polymerization reaction products in which mock-phos-
phorylated tau had been polymerized. In panel C and D, 
GSK-3β had been omitted from the phosphorylation reac-
tion (- GSK + ATP) and in panel E and F, ATP had been omit-
ted from the phosphorylation reaction (+ GSK – ATP). The 
25 μM ARA reactions were diluted five fold, the 75 μM ARA 
reactions were diluted ten fold prior to grid preparation.
Clustering of filaments polymerized from phosphorylated tauFigure 4
Clustering of filaments polymerized from phosphor-
ylated tau. Samples from the 25 μM ARA-induced phospho-
rylated tau reaction (20 h) shown in Figure 3, were diluted 
five-fold and prepared for transmission electron microscopy 
(TEM). Panels A, C and E show representative clusters of fila-
ments at a magnification of 50,000 × (scale bar represents 
500 nm). Panels B, D and F show the same clusters at a mag-
nification of 100,000 × (scale bar represents 100 nm). In the 
higher magnification micrographs, white arrowheads denote 
non-touching filaments; white asterisks, branching filaments; 
and black arrowheads, tendril-like fibrils that appear to later-
ally connect larger adjacent filaments.Page 6 of 14
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ble that its primary effect on cluster formation came not
from its role as a kinase but from a hypothetical role as
NFT or cluster "glue". To determine the role of GSK-3β, we
carried out two mock phosphorylation reactions, one in
which the GSK-3β was omitted (Figure 5C, D), the other
in which the ATP was omitted (Figure 5E, F). Omission of
ATP mimics the GSK-3β inhibitors that act by competing
for ATP. Without ATP in the phosphorylation reaction, no
filament clustering occurred in the polymerization reac-
tion (Figure 5E, F) and none of the mock phosphorylation
reactions showed a band shift on SDS-PAGE (data not
shown). Since GSK-3β did not support filament clustering
without ATP it would seem that phosphorylation of tau is
the primary role of GSK-3β in cluster formation. Although
polymerization of the mock-phosphorylated tau induced
by 25 μM ARA showed no filament clustering if either
GSK-3β or ATP were omitted (Figure 5C and 5E), at high
ARA concentration (75 μM) we did observe a few small fil-
ament clusters when ATP was present without GSK-3β,
suggesting that high inducer concentration plus ATP
might partially compensate for tau phosphorylation in
cluster formation.
To determine whether phosphorylation by GSK-3β alone
was sufficient to promote tau filament clustering, phos-
phorylated tau was polymerized without the ThS present
in the samples from the kinetic study. This was important
since high concentrations of ThS (100 μM) have been
shown to induce polymerization of monomeric tau [42]
and possibly, a lower concentration of ThS was required
in addition to phosphorylation to promote cluster forma-
tion. TEM analysis showed that phosphorylation alone
was sufficient to promote cluster formation with either
ratio, 25 or 75 μM ARA:2 μM tau (Figure 6A, B). However,
especially with the suboptimal inducer:tau ratio (25 μM
ARA), the cluster morphology appeared to change with
the addition of ThS (Figure 6, compare A with C). None of
the clusters formed with the optimal ARA:tau ratio (75 μM
ARA) were as tightly packed as those with 25 μM ARA and
20 μM ThS (Figure 6, compare B and D with C). These
apparent differences in cluster morphology suggested that
inducer concentration and/or ThS might be cluster modi-
fiers.
Morphological characteristics of filament clusters
To verify our TEM observations (and to assess the statisti-
cal significance of potential modifying reagents), the
number of filaments and the average filament length in
each cluster, as well as the area covered by each cluster
were measured. These cluster properties, average filament
length, filament number, area covered, and density
allowed us to quantify cluster morphology and assess the
modifying effects of various reagents.
We first compared clusters formed by polymerizations of
phosphorylated tau plus ThS (+phos.+ThS) that were
induced with 25 μM ARA to those induced with 75 μM
ARA (Figure 7). The comparison showed that the average
length of the filaments within each cluster was signifi-
cantly increased with the optimal (75 μM) ARA concentra-
tion (Figure 7A, D) (P < 0.0001), as was the area covered
by each cluster (Figure 7B, C) (P = 0.0148). However, the
clusters were less densely packed than those formed with
25 μM ARA (Figure 7E) (P = 0.0014). These properties are
summarized in Figure 7C, D, and 7E, and are in agree-
ment with the representative TEM micrographs of Figure
6C and 6D. The ratio of inducer:tau in the polymerization
reaction apparently affects one or more of these properties
of cluster morphology and determines how the filaments
interact to affect size and density of the clusters. These
measurements demonstrate that cluster morphology can
be defined by quantitative measurements and that the
morphology can be modified by specific reaction condi-
tions.
Effect of ThS on filament formation
TEM micrographs suggested that ThS might also modify
cluster morphology (Figure 6). To isolate the effect of ThS
on filament formation, we examined wild type, non-
Phosphorylation by GSK-3β is sufficient to promote filament clusteringFigure 6
Phosphorylation by GSK-3β is sufficient to promote 
filament clustering. Panel A and B show products of phos-
phorylated and polymerized tau (+phos.). Panel C and D 
show products of phosphorylated tau that was polymerized 
in the presence of 20 μM ThS (+phos., +ThS). The clusters of 
filaments were approximately 2 μm across their longest axis. 
Magnification was 20,000 × (scale bar represents 500 nm). 
Panels A and C were induced with 25 μM ARA and diluted 
five fold prior to grid preparation; Panels B and D were 
induced with 75 μM ARA, and diluted 10 fold.Page 7 of 14
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Effects of ThS on filament formationFigure 8
Effects of ThS on filament formation. Polymerization 
reactions were carried out with 2 μM non-phosphorylated 
tau under standard conditions with low (25 μM) or optimal 
(75 μM) ARA inducer:tau ratios without (white bars) or with 
(black bars) ThS. Error bars represent the SEM. Panel A is a 
comparison of the number of filaments; Panel B is a compari-
son of average length of filaments; and Panel C is the calcula-
tion of filament "mass" (detailed in Materials and Methods).
Morphological characteristics of clustersFigure 7
Morphological characteristics of clusters. The average 
length of filaments in a cluster (Panel A) and the area covered 
by each cluster (size) (Panel B) were determined and plotted 
against the calculated density of the cluster. Each cluster is 
represented separately in Panels A and B. This data was then 
averaged and summarized in Panel C (area), Panel D (filament 
length) and Panel E (density). Polymerization products from 
25 μM ARA-induced polymerization reactions are presented 
as white circles and bars; those from 75 μM ARA induction 
are presented as black circles and bars. Error bars are +/- 
SEM.
Molecular Neurodegeneration 2007, 2:12 http://www.molecularneurodegeneration.com/content/2/1/12phosphorylated tau polymerization reactions with and
without ThS (Figure 8A–C). The presence of ThS resulted
in a significant increase in the number of filaments (Fig-
ure 8A), a significant decrease in average filament length
(Figure 8B), and a significant increase in the calculated
mass of filaments per field (Figure 8C) for both 25 μM
and 75 μM inducer concentrations (all P values were
<0.0001). This data suggests that conditions which pro-
duce shorter filaments promote formation of a tighter and
more densely packed cluster.
Comparison of filament clusters formed in vitro to NFT-
like filament bundles isolated from AD brain
In order to compare the similarity of the clustered fila-
ments in our in vitro cell-free system to isolated NFT-like
bundles of tau filaments from AD brain, polymerization
reaction products were fractionated using centrifugation
through a discontinuous gradient of 1.0, 1.5 and 2.0 M
sucrose in polymerization buffer. The procedure was
based on a published protocol for separating individual
tau filaments from NFT-like bundles of tau filaments iso-
lated from AD brain [33,34]. Following centrifugation,
numerous clusters of phosphorylated filaments accumu-
lated at the 1.5/2.0 sucrose interface (Figure 9C and 9D),
the same place that the larger NFT-like bundles of tau fil-
aments from human AD brain had accumulated [33]. A
few very small clusters of mock-phosphorylated tau fila-
ments were also found (Figure 9A, B). Since we previously
found that mock phosphorylation conditions containing
ATP in the absence of GSK-3β did produce a small
number of tangles at a high ARA:tau ratio (Figure 5D), it
is conceivable that tangles might also form, albeit more
rarely, with the suboptimal ratio (25 μM ARA). However,
due to the rare occurrence of tangles under these condi-
tions, concentration by the sucrose gradient was required
for detection. Since proteins migrate in density-gradient
(zonal) centrifugation according to weight, density and
shape, the sucrose gradient experiment suggests that the
clustered filaments formed in vitro and the larger aggre-
gates isolated from AD brain share similar properties. Fur-
thermore, the in vitro filament aggregates are quite stable,
maintaining their distinctive morphology through
sucrose gradient centrifugation and extensive washing
prior to examination by TEM.
Discussion
Due to the controversial role of neurofibrillary tangle
(NFT) formation in the neurodegenerative process [2-4,6-
9,43-47], a better understanding of the mechanisms lead-
ing to the formation of NFT would be beneficial to our
understanding of AD.
In this report, we have demonstrated that GSK-3β phos-
phorylation of tau is sufficient to induce the clustering of
ARA-induced filaments into structures similar to the NFT-
like aggregates of tau filaments purified from AD brain
[33,34]. These results suggest that GSK-3β phosphoryla-
tion not only produces a small but significant increase in
tau filament formation, but also shows that phosphoryla-
tion alters the nature of interactions between those fila-
ments resulting in their clustering into NFT-like
structures. Although in this report we address only the
effects of tau phosphorylation by GSK-3β, ARA inducer
concentration (the inducer:tau ratio in polymerization),
and ThS on the clustering of tau filaments into NFT-like
structures, we feel that this is an important first step in
unraveling the molecular mechanisms of NFT formation
through cell-free in vitro modeling.
The clusters of tau filaments formed by polymerization of
GSK-3β phosphorylated tau are stable and their formation
is readily reproducible, although various factors influence
the size, mass and density of the clusters. Here we demon-
strate the effects of inducer and the ratio of inducer:tau
concentration on these properties. In general, we have
found that phosphorylation by GSK-3β is sufficient for
Sucrose gradient centrifugation of polymerization reactionsFigure 9
Sucrose gradient centrifugation of polymerization 
reactions. Polymerization reactions containing ARA, ThS 
and either mock-phosphorylated (minus GSK-3β), or phos-
phorylated tau were centrifuged through a discontinuous 
sucrose gradient containing 1.0, 1.5, and 2.0 M sucrose. Fila-
ment clusters sedimented at the interface of the 1.5 and 2.0 
M sucrose concentrations. Panels A, and C are TEM micro-
graphs of gradient fractions from reactions induced with a 
low inducer:tau ratio (25 μM ARA:2 μM tau, panels B and D 
with an optimal ratio (75 μM ARA:2 μM tau). Grids were 
prepared without glutaraldehyde fixation of polymerization 
samples. Samples were concentrated five fold on the TEM 
grids.Page 9 of 14
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ment length modify both the density of the filaments in
the cluster, and the size of the cluster. Increases in inducer
concentration which result in a change from the subopti-
mal to optimal ratio of inducer:tau concentration in the
polymerization reaction increase the filament length
within clusters and the area covered by the clusters. This
results in clustered filaments that are less densely packed.
Conversely, conditions that decrease filament length pro-
duce smaller clusters that contain a higher density of fila-
ments.
With this newly developed in vitro model, we can begin to
dissect the molecular mechanisms that are involved in fil-
ament aggregations that form NFT-like structures. Further
studies will be aimed at understanding whether GSK-3β
phosphorylation unmasks regions of tau molecules that
interact with one another in forming clusters or whether
the GSK-3β phosphorylation sites are interacting directly.
It is tempting to speculate a role for the former since GSK-
3β phosphorylation results in an SDS-resistant conforma-
tional change as observed by an upward shift in mobility
on SDS page analysis. The apparent increase in initial
polymerization velocity as monitored by ThS fluorescence
also suggests that the GSK-3β phosphorylated tau may be
in a conformation that more readily interacts with the
ARA inducer or with the ThS as used to detect amyloid-
type interactions in tau kinetic analyses. Although the co-
localization of GSK-3β with tau pathology in AD suggests
that NFTs may form from the direct interaction of GSK-3β
with tau filaments [15], our mock-phosphorylation
results strongly suggest that phosphorylation is the pri-
mary role of GSK-3β in promoting cluster formation.
This in vitro model for NFT formation requires the induc-
tion of tau polymerization via the addition of ARA, which
may lead to the questioning of its physiological relevance.
An inducer of tau polymerization in AD and other neuro-
degenerative disorders has not been identified, but that
does not dampen our enthusiasm for the use of ARA as an
inducer in our cell-free in vitro model system. This is due
to ample evidence that ARA induced tau filaments are
structurally similar to filaments from AD [42,48-51].
Additionally, there is growing evidence that ARA or its
metabolites could be involved in the neurodegenerative
process in AD (reviewed in [52]). While a direct connec-
tion between tau polymerization and ARA remains to be
made in AD, the structural similarity between ARA
induced filaments and AD filaments, plus the similarity
between GSK-3β induced NFT-like clusters of tau fila-
ments and those found in AD provide a strong argument
for the physiological relevance of this model. In addition
to the characterization of the GSK-3β induced clustering
of filaments, this in vitro model provides a tool for inves-
tigating whether other kinases such as cyclin dependent
kinase 5 or microtubule affinity regulating kinase have
similar properties to induce the formation of NFT-like fil-
ament bundles. Likewise, other modifications found in
association with AD NFTs, such as truncation, ubiquitina-
tion, nitration and glycation (reviewed in [1,10]) could
also be tested. Our hope is that these ongoing studies will
isolate factors contributing not only to the formation of
NFT-like clusters, but also to identify the conditions that
could lead to potentially toxic tau aggregates in cell and
animal culture models.
Methods
Reagents and Supplies
Arachidonic acid was obtained from Cayman Chemicals
(Ann Arbor, MI), thioflavine S and recombinant glycogen
synthase kinase 3β (GSK-3β) from Sigma (St. Louis, MO),
and uranyl acetate and formvar carbon coated grids from
Electron Microscopy Sciences (Hatfield, PA). SDS-PAGE
markers are Precision Plus Protein Standards from Bio-
Rad (Hercules, CA).
Tau protein
Tau protein (441 amino acids containing exons 2, 3 and
10) was expressed in and purified from BL21 E. Coli as
described previously [32]. Protein concentration was
determined using the Pierce BCA assay (Pierce Biotech-
nology, Rockford, IL). The purity of the protein was
assessed by SDS-PAGE electrophoresis.
Phosphorylation of tau by GSK-3β
Determination of optimal phosphate incorporation
Tau protein at a final concentration of 16 μM was incu-
bated with either 0.006 or 0.018 U GSK-3β per pmol tau
in buffer containing 40 mM HEPES, pH 7.64, 5 mM
EGTA, 3 mM MgCl2, and 2 mM ATP for 20 h at 30°C. One
unit of GSK-3β is defined as the amount of enzyme that
will transfer one pmol phosphate from ATP to phos-
phatase inhibitor 2 per min at pH 7.5 at 30°C. Samples
were removed at various times from the phosphorylation
reaction, then boiled in Laemmli sample buffer [53] for 5
minutes to stop phosphorylation. One microgram of tau
protein from the reaction time points was analyzed by
SDS-PAGE.
Determination of gel band shift
SDS-PAGE gels from posphorylation reactions were con-
verted to digital images using an HP Scanjet 7400c scan-
ner (Hewlett-Packard company, Palo Alto, CA). The gels
were converted to grayscale and inverted using Adobe
Photoshop (Adobe Systems Incorporated, San Jose, CA).
Two fixed size marquees were used to determine the aver-
age intensity of pixels from the entire sample in a lane or
only the area corresponding to the shifted band. The aver-
age intensity of the gel background was subtracted. The
percentage of tau in the shifted band was determined byPage 10 of 14
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Determination of phosphate incorporation
Tau protein at a final concentration of 16 μM was incu-
bated with 0.018 U GSK-3β per pmol tau in buffer con-
taining 40 mM HEPES, pH 7.64, 5 mM EGTA, 3 mM
MgCl2, and 2 mM ATP containing 10 μCi [γ-32P] labeled
ATP (Specific activity: 3000 Ci/mmol) (Perkin-Elmer,
Boston, MA) for 20 h at 30°C. Samples were removed at
various times from the phosphorylation reaction, diluted
and filtered through a Millipore ULTRAFREE 10,000
molecular weight cut off filter (Millipore, Billerica, MA).
Samples were washed with two-250 μl volumes buffer
containing 5 mM DTT, 100 mM NaCl, 10 mM HEPES pH
7.64, and 0.1 mM EDTA. γ-32P incorporation in tau was
measured using a Packard 1600TR liquid scintillation
counter to measure the radioactivity in the retentate and
filter. The protein content of the flow-through filtrate was
assayed by the BCA microplate protocol (Pierce Biotech-
nology, Rockford, IL) and was below the minimum
detectable amount (20 μg/ml), allowing the assumption
that no protein was lost during the filtration process. The
amount of phosphate per protein molecule was calculated
using the specific activity of γ-32P and the molar concen-
tration of tau.
Generation of GSK-3β phosphorylated tau for further analysis
Based on the results above, we determined that the opti-
mal phosphate incorporation was achieved by incubating
16 μM tau with 0.018 U GSK-3β per pmol of tau in buffer
containing 40 mM HEPES, pH 7.64, 5 mM EGTA, 3 mM
MgCl2, and 2 mM ATP for 20 h at 30°C. These conditions
were used to generate GSK-3β phosphorylated tau for use
in Figures 2, 3, 4, 6, 7, and 9.
Mock-phosphorylated tau
Two separate conditions were used to generate "mock"
phosphorylated tau analyzed in Figure 5. The first was by
eliminating GSK-3β from the reaction such that the phos-
phorylation reaction consisted of 16 μM tau in buffer con-
taining 40 mM HEPES, pH 7.64, 5 mM EGTA, 3 mM
MgCl2, and 2 mM ATP for 20 h at 30°C and was also used
as a control in Figure 9. The second was by eliminating
ATP from the reaction such that the phosphorylation reac-
tion consisted of 16 μM tau with 0.018 U GSK-3β per
pmol of tau in buffer containing 40 mM HEPES, pH 7.64,
5 mM EGTA, and 3 mM MgCl2, and then incubated for 20
h at 30°C.
Dot blots of phosphorylated tau protein
Phosphorylated tau was diluted in TBS (20 mM Tris pH
7.5, 150 mM NaCl) such that 3 μl of the dilution con-
tained the desired amount of protein. The protein (3 μl)
was spotted onto Immobilon P membrane which was pre-
pared according to manufacturer's instructions (Millipore,
Billerica, MA). Blots were blocked for 1 h in TBS contain-
ing 1% BSA and 2% normal goat serum. The primary, tau
phosphorylation-specific antibodies (Biosource Interna-
tional, Camarillo, CA) were diluted 1:1000 in blocking
solution and blots were rotated overnight at 4°C. Blots
were washed with TBS/Tween 20 (0.1%)/NP40 (0.05%),
blocked with blocking buffer and incubated with an alka-
line phosphatase conjugated anti-rabbit IgG secondary
antibody (Sigma, St. Louis, MO). Blots were developed
with chemiluminescence reagent, CDP-Star (PerkinElmer
Life Sciences, Boston, MA). Images were captured on a
Kodak Image Station 4000R (Eastman Kodak Co, Molec-
ular Imaging Systems, Rochester, NY), and analyzed using
the Array Analysis feature of the ImageQuantTL v2003.03
software that accompanies the Typhoon Trio, Variable
Mode Imager (Amersham Biosciences, Piscataway, NJ).
After subtracting non-specific binding data (density of the
non-phosphorylated tau dots for each concentration), the
density data was plotted using GraphPad Prism 4 Graph-
Pad Software Inc., San Diego, CA).
Tau polymerization reactions
Standard polymerization reactions
Tau was diluted to a final concentration of 2 μM into
buffer containing 10 mM HEPES, pH 7.64, 100 mM NaCl,
0.1 mM EDTA, and 5 mM DTT. Arachidonic acid (ARA)
was added to a final concentration of either 25 or 75 μM
to induce polymerization. Standard polymerization reac-
tion conditions were used as controls for Figures 3, 5 and
8.
Polymerization of phosphorylated tau
In polymerization reactions using phosphorylated tau,
the phosphorylation reaction was diluted to a final con-
centration of 2 μM into polymerization buffer containing
10 mM HEPES, pH 7.64, 100 mM NaCl, 0.1 mM EDTA,
and 5 mM DTT. This resulted in some minor buffer addi-
tions: 0.625 mM EGTA, 0.375 mM MgCl2, 0.25 mM ATP
and increased the final HEPES concentration to 15 mM.
These buffer additions did not appear to affect polymeri-
zation. The GSK-3β that carried over from the phosphor-
ylation reaction was not de-activated. Phosphorylation
reaction products were analyzed by coomassie blue stain-
ing on 10–15% SDS-PAGE prior to use in polymerization
reactions.
Polymerization of mock phosphorylated tau
The mock phosphorylation reaction was diluted into
polymerization buffer to a final concentration of 2 μM tau
as above, except that there was no carry over of GSK-3β or
of ATP if those reagents were omitted from the mock
phosphorylation reaction.Page 11 of 14
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Polymerization reactions with ThS contained 2 μM non-
phosphorylated tau in buffer containing 10 mM HEPES,
pH 7.64, 100 mM NaCl, 0.1 mM EDTA, 5 mM DTT and
20 μM ThS. ARA was added to a final concentration of 25
or 75 μM to induce polymerization. Reactions with phos-
phorylated or mock phosphorylated tau resulted in minor
buffer additions (described above). ThS containing reac-
tions were used in Figure 3 to compare levels of polymer
for the kinetics study and also for Figures 4, and 6, 7, 8, 9.
Kinetics
The kinetics of polymerization reactions were assayed by
ThS fluorescence, utilizing a FlexStation II fluorometer
microplate reader (Molecular Devices Corporation, Sun-
nyvale, CA). Settings included: Excitation λ = 440, Emis-
sion λ = 520, PMT = high. Polymerization reactions
containing all reagents except ARA were prepared. The
FlexStation II automatically added the ARA and began flu-
orescence intensity readings thirteen seconds later. Read-
ings were taken every 1.5 seconds for the first 30 minutes,
then once every 5 minutes for 20 hours.
Electron microscopy of tau filaments and filament clusters
Grid preparation
Samples were diluted either by a factor of five (25 μM ARA
reactions) or ten (75 μM ARA reactions) in polymeriza-
tion buffer, then applied to the grids, allowing one minute
for filaments and/or clusters to attach. The edge of the grid
was then touched to filter paper to blot away excess liquid.
Grids were stained with 1% uranyl acetate for one minute
then blotted as above. Grids were viewed with a JEOL
1200 EXII electron microscope and images were captured
with the MegaViewII imaging system (Soft Imaging Sys-
tem, GmbH Münster, Germany).
Measurements of tau filaments and filament clusters
The area, mass and density of localized accumulations of
tau filaments on electron microscopy grids were measured
using the Optimas analytical imaging software (Media
Cybernetics, Silver Spring, MD) and GraphPad Prism soft-
ware (Graphpad Software, San Diego, CA). Digital elec-
tron micrographs were collected at 20,000 ×
magnification. For measurements of individual filaments,
the entire field was selected using the "threshold tool" and
"auto find lines" feature of the software. For clusters of fil-
aments, the region of interest tool was used to outline the
clusters of filaments in Optimas. Filaments within the
clusters were selected using the "threshold tool" and the
"auto find lines". For a field of individual filaments or for
filaments in the selected "area of interest" cluster, the
number and average length of filaments was determined
and multiplied to obtain an estimate of filament mass in
the field or region of interest. For clusters, the "draw area
tool" was used to outline the outer boundary of the fila-
ments in order to obtain the area occupied. The total sum
length of filaments was divided by the area occupied by
those filaments to obtain measurements for the density of
the filament clusters.
Discontinuous Sucrose Gradients
Centrifugation of tau polymerization reactions through
discontinuous gradients consisting of 1, 1.5 and 2 M
sucrose were performed as previously described [33],
except that sucrose was dissolved in buffer containing 5
mM DTT, 100 mM NaCl, 10 mM HEPES, and 0.1 mM
EDTA. Polymerization reactions were overlaid on the gra-
dient and centrifuged at 100,000 × g for 2 h in a TLA 100.3
rotor (Beckman-Coulter, Fullerton, CA). To compensate
for any reduction of filament adherence due to sucrose in
the samples, gradient fraction samples were applied 5
times to the formvar carbon coated electron microscopy
grids, allowing 1 minute each time for filaments to attach.
Grids were rinsed five times with polymerization buffer
and stained with 0.5% uranyl acetate for 1 minute. There-
fore, the filaments viewed by electron microscopy were
concentrated five fold in addition to any concentration of
filaments produced by the centrifugation through the gra-
dient.
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